Munich, Germany, February 28, 2014 – Sandoz announced today it has received South Korean marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD, marking its first approval in Asia.

The product was first approved in Denmark on December 18th, 2013, with subsequent approvals in Germany, Belgium, Sweden, Norway, Hungary, Romania and Bulgaria.

“We are pleased to receive the marketing authorization in South Korea for AirFluSal® Forspiro®. This is our first approval in Asia and outside Europe and a milestone in …

March 7, 2014

Today Sandoz recognizes International Women’s Day (IWD), a globally-recognized day which celebrates the economic, social and cultural contributions made by women.

It is observed each year on March 8th. The United Nations theme for IWD this year is “Equality for Women is Progress for All.”

…

March 14, 2014 – Sandoz 1 A Pharma is pleased to participate in the develoPPP.de (DPP) project “Quality Assured Essential Medicines for Ghana,” a three-year development partnership aimed at increasing access to high-quality, affordable medicines for patients in Ghana.

The project will be led by the German International Cooperation Agency, Deutsche Gesellschaft fuer Internationale Zummenarbeit GmbH (GIZ) and financed by the German Federal Ministry for Economic Cooperation and Development (BMZ).

The DPP project will focus on increasing access to medicines …

Holzkirchen, Germany, February 24, 2014 – Sandoz officially opened its representative office in Accra, Ghana on January 23, 2014.

The ceremony was attended by healthcare professionals including pharmacists, doctors, the Ghana health service, the Ministry of health, as well as Brigitte Cuendet, the Counsellor and Head of Economic Affairs at the Swiss Embassy in Ghana, and Edith Gavor, manager of the Ghana National Drug Programme (GNDP).

Ms …

Holzkirchen, Germany, February 12, 2014 – Sandoz announced it has received marketing authorization in Belgium for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

The product was first approved in Denmark on December 18th, 2013 with subsequent marketing authorizations received in Germany, Sweden, Hungary, Romania, Bulgaria, and Norway.

The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

Belgium has …